AstraZeneca PLC
AZN: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 69,815.00 | Vwrw | Xfnfzptq |
AstraZeneca Earnings: Core Product Growth and Strong Pipeline Advancement Offset Lost COVID-19 Sales
AstraZeneca reported solid first-quarter results slightly above our expectations, but we don’t expect any major change to our fair value estimate. While COVID-19 product sales were down as expected with the pandemic receding, core products continue to post solid growth while the pipeline is making excellent strides to reinforce the firm’s wide moat.